UK markets closed

ArcticZymes Technologies ASA (0DRV.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
6.60-59.40 (-90.00%)
At close: 2:35PM BST

ArcticZymes Technologies ASA

Sykehusveien 23
PO Box 6463
Tromsø 9294
Norway
47 77 64 89 00
http://arcticzymes.com

Sector(s)
Industry
Full-time employees36

Key executives

NameTitlePayExercisedYear born
Dr. Jethro HolterChief Exec. Officer1.49MN/A1972
Mr. Børge SørvollChief Financial Officer1.33MN/A1975
Ms. Marit Sjo LorentzenEmployee Representative Director & Director of OperationsN/AN/AN/A
Mr. Alexander Johann BjornaDirector of IP & Bus. Devel.N/AN/AN/A
Mr. Dino DiCamilloDirector of MarketingN/AN/A1958
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.

Description

ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. It operates through two segments, Enzymes and Beta-Glucans. The company provides recombinant enzymes that are primarily derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of DNA from RNA samples; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company also provides immunomodulating beta-glucans products for the wound care, animal and consumer health, and adjuvants markets. It offers Woulgan wound gel; M-Glucan, a natural immune-stimulating product for fish and animal feed; and M-Gard, a natural immune-stimulating ingredients to enhance physical health. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Corporate governance

ArcticZymes Technologies ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.